Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.
Legend Biotech Corp (NASDAQ: LEGN) is a clinical-stage biopharmaceutical leader in developing CAR-T cell therapies for oncology, including multiple myeloma. This page serves as the definitive resource for tracking LEGN's corporate developments, research breakthroughs, and regulatory milestones.
Investors and industry professionals will find timely updates on clinical trial results, partnership announcements, and strategic initiatives driving innovation in cell therapy. The curated news collection provides transparent access to primary source materials while maintaining compliance with financial disclosure standards.
Key content categories include clinical trial updates, regulatory filings, research collaborations, and business development activities. Each news item is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for direct access to Legend Biotech's official communications and expert analyses of their pioneering work in cancer immunotherapy. Regularly updated to reflect the latest advancements in CAR-T technology and oncology treatment development.
Legend Biotech (NASDAQ: LEGN), a global leader in cell therapy, announced that CEO Ying Huang, Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference. This event will take place in New York, NY, on June 6, 2024, at 10:30 a.m. ET. Investors and other interested parties can view the live webcast through the Investor Relations section of Legend's website. A replay will be available approximately 48 hours after the event.
Legend Biotech (NASDAQ: LEGN) will present new data on its CAR-T cell therapy, CARVYKTI®, for multiple myeloma at the 2024 ASCO and EHA events.
Significant upcoming presentations include:
- Phase 2 CARTITUDE-2 study data will be presented at ASCO and EHA.
- Phase 3 CARTITUDE-4 study data regarding high-risk multiple myeloma will also be showcased.
Key studies analyze CARVYKTI®'s effectiveness in patients with different risk profiles and those who had suboptimal responses to previous treatments.
Despite positive advancements, warnings about severe side effects such as cytokine release syndrome, neurologic toxicities, and other serious adverse events were noted.
Legend Biotech (NASDAQ: LEGN) reported first quarter 2024 financial results with CARVYKTI® net trade sales of $157 million, FDA label expansion, and a milestone payment of $45 million. The company's cash position stands at $1.3 billion, ensuring financial stability until 2026. Legend Biotech's recent developments include increased manufacturing capacity, regulatory approvals in the U.S., Europe, and Brazil, and a Master Manufacturing and Supply Services Agreement with Novartis. The company's ESG report aligns with SASB standards, and the collaboration revenue has shown significant growth.
FAQ
What is the current stock price of Legend Biotech (LEGN)?
What is the market cap of Legend Biotech (LEGN)?
